Illegal Activity
none
Blackmail
none
Date
January 2018
Document Type
Research Report
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41
Summary
This document is a Deutsche Bank research report providing a "BUY" recommendation for Shire stock, with a target price of 5000p. The report highlights Shire's growth potential, undervaluation, and new pipeline opportunities.
Metadata
- Subject
- Shire Stock Analysis
- Sender
- Deutsche Bank
- Recipients
- —
- Document ID
- DB-SDNY-0086803
- Date
- January 2018
Relationships 1
| Entity 1 | Relationship | Entity 2 | Description |
|---|---|---|---|
| Deutsche Bank | Financial Analysis | Shire | Deutsche Bank provides a stock analysis of Shire. |
Notable Quotes 2
Shares are far too cheap at just 8x 19E PE and 9x EV/EBITDA.
Consensus has overlooked new pipeline opportunities. We see positive surprise potential on these programmes, particularly if clinical data supports attractive pricing for SHP621 (est. 150k patients in the US alone, many of whom have few effective treatments).
Financial Information
Amounts:3875p5000p150k
Assets:
- Shire stock
Public Knowledge
- Context
- Stock analysis reports are often of interest to investors and the media.
- Media Worthy
- Yes
Raw Analysis JSON
click to expand
Themes
Financial transactions/money flowBusiness dealings
People 1
Organizations 4
HealthcareDeutsche BankShirePharma
Locations 1
US
Financial Entities 1
Deutsche Bank
Text Analysis
- Tone
- Professional
- Purpose
- To provide an investment analysis and recommendation for Shire stock.
- Significance
- The document provides a financial analysis of Shire, including target prices, growth expectations, and competitive threats.
File Info
- File Name
- EFTA01385517.txt
- Dataset
- dataset_10
- Type
- Text
- Model
- gemini-2.0-flash-001
- Processed
- 2026-02-07T18:41:16.753712
- DOJ Source
- View on DOJ